AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Medistim

AGM Information Apr 26, 2017

3662_rns_2017-04-26_90025a4c-b766-4a33-a044-78ed81e61fc6.pdf

AGM Information

Open in Viewer

Opens in native device viewer

MINUTES FROM THE GENERAL MEETING IN MEDISTIM ASA

Medistim ASA held its ordinary general meeting Wednesday the 26th of April 2017 at 10.00. The meeting was held at the company offices in Økernveien 94 in Oslo. Attachment 1 gives an overview of the shareholders that were represented. 42.26 % of the shareholders were represented were 15.71 % were represented by proxy.

Chairman of the Board of Director's Øyvin Anders Brøymer opened the meeting.

The agenda for the meeting was as follows:

1. Approval of notice and power of attorney

There were no comments to the notice, the agenda or proxies and these were approved. The meeting was pronounced lawfully called and assembled.

2. Appointment of person to chair the meeting, to sign the protocol, to co-sign the protocol and protocol secretary

Øyvin Anders Brøymer was chosen to chair the meeting. Asbjørn Buanes and Kari Krogstad were chosen to sign the minutes together with Øyvin Brøymer. Thomas Jakobsen was chosen as secretary for the meeting. All elections were unanimously chosen.

3. Approval of annual report for 2016

The Chairman of the meeting went through the annual report for 2016. The General Assembly took note of this and there were no comments to the report.

4. Approval of the income statement and balance sheet for 2016

The income statement and balance sheet for 2016 was presented for the holding company and the group to the general meeting by the chairman of the meeting. The general meeting took notice of the presentation and there were no comments to the presentation. The income statement for 2016 and balance sheet for 2016 for the holding company and the group were approved.

5. Allocation of profit for 2016

The profit for 2016 was TNOK 41,715 for the holding company. The Board of Directors suggested a dividend to the shareholders of NOK 1.75 per share, total TNOK 31,782 and that TNOK 9,933 is transferred to other equity. The company has 176,000 Medistim shares and does not pay dividend on own shares. Shareholders registered in VPS by the end of the 26th of April 2017 will have the right to the dividend. The Board of director's suggestion was approved unanimously by the general assembly. The Medistim shares will be traded as ex dividend NOK 1.75 as of the 27 of April.

6. The Board of Director's declaration on salary and other remuneration to the management

The Chairman gave an orientation to the general meeting of the principals used to set salary and remuneration to the management and key personnel. The declaration is also described in the annual report. The general meeting took notice of the orientation. Of a total of 7,749,746 votes, 6,076,874 of the votes approved the principles, while 1,672,872 of the votes where against the principles. As a conclusion the General Meeting approved the principals for salary and remuneration to management and key personnel.

7. Approval of fee to the auditor

Fee to the auditor was in total TNOK 431 where TNOK 390 was for the audit and TNOK 41 was for other services. The fee to the auditor was approved by the general meeting.

8. Election of board members. Two of the board members are on election

Two of the board members, Chairman Øyvin Anders Brøymer and board member Siri Fürst, were on election for a new term of two years. The nomination committee recommends that both candidates are elected for a new term of two years. The candidates were unanimously elected, Øyvin Anders Brøymer as Chairman and Siri Fürst as board member for a two year term until ordinary general meeting in 2019.

9. Approval of fee to the Board of Director's

The fee to the Board of Director's in 2016 was NOK 350.000 to the Chairman. Fee to the board members was NOK 200.000 to 4 members. Total fee for 2016 was NOK 1,150,000. The fee to the Board of Director's was approved by the general meeting.

10. Election of members to the nomination committee

The members of the nomination committee was on election. This was Bjørn Henrik Rasmussen and Asbjørn Buanes, which represent Medistim's fourth and eight largest shareholders respectively. Bjørn Henrik Rasmussen and Asbjørn Buanes were willing to take a new term and was re-elected for a new term of two years.

11. Approval of fee to the nomination committee

It was suggested to the General Meeting that the leader of the Nomination Committee was compensated with 20 TNOK and that the members were compensated with 15 TNOK. Total purposed fee to the Nomination Committee was 50 TNOK. Of a total of 7,749,746 votes, 6,401,874 of the votes approved the fee to the nomination committee, while 1,347,872 of the votes where against the fee to the nomination committee. The fee to the nomination committee was approved by the general meeting.

12. Approval of the Board of Director's suggestion to the general meeting to renew the Board of Director's authorisation to increase share capital.

The general meeting gave the Board of director's approval to increase share capital on the following terms and conditions:

  • A. The Board of Director's is authorised to increase share capital up to NOK 458,433.25 by issuing up to 1,833,733 new shares at par value of NOK 0.25. The share price and other terms when issuing new shares are set by the board of directors. The board of directors can increase the share capital once or in several different occasions.
  • B. In case of a change in par value of the share as a result of a split, fond emission or something similar, is the authorisation adjusted accordingly with the number of shares that can be issued. The share price and other terms are adjusted according to generally known principles for such adjustments, but always within the regulations in the Public Limited Companies Act.
  • C. The authorisation shall also include capital increase against other assets than cash deposits.
  • D. The shareholders preferential rights to subscribe shares can be set aside by the board according to the Public Limited Companies Act § 10-4.
  • E. The authorisation shall include a decision including a fusion according to Public Limited Companies Act § 13-5.
  • F. The authorisation is valid until the next ordinary general meeting.

The general meeting approved the Board of Director's authorisation to increase share capital unanimously according to the above terms and conditions.

The general meetings resolution will be registered in the Brønnøysund register centre and must be registered before the Board of Directors can use the authorisation.

13. Approval of authorisation to purchase own shares

The general meeting gave the board of directors renewed power of attorney to purchase own shares on the following terms and conditions:

  • A. The authorisation is valid until the next general meeting.
  • B. The company can purchase shares at par value up to NOK 458,433.25, which are 1,833,733 shares at today's par value.
  • C. The highest price per share shall maximum be NOK 100.00 per share.
  • D. The lowest price per share shall minimum be NOK 0.25 per share.
  • E. The Board of Director's can freely decide how to purchase the shares as long as the principle for equal treatment is followed.

The general meeting approved the power of attorney to purchase own shares unanimously according to above terms and conditions.

The general meeting resolution must be registered in the Brønnøysund register centre before the board can use the authorisation.

* * *

There were no other issues on the agenda. The meeting was ended and the minutes signed.

Oslo 26. April 2017

_____________ _________________ ___________________

Asbjørn Buanes Øyvin A. Brøymer Kari Eian Krogstad Sign. Sign. Sign.

Results of the voting and participation at the General meeting in Medistim ASA the 26th of April 2017 Enclosure to General Meeting protocol

Res
ults
of
the
n th
e G
ral m
ing
in M
edis
tim
ASA
vot
eet
es o
ene
In fa
vou
r
Aga
inst
Abs
tain
1. A
l of
the
ice,
istra
tion
of
sha
reh
olde
ted
by
not
ppr
ova
reg
rs o
r pe
rson
s re
pre
sen
pro
xy.
7 58
7 38
8
162
358
2. A
intm
of
cha
ir th
ing,
sign
the
ol, t
‐sig
n th
col
and
ol s
ed i
n th
al m
ing.
ent
to
eet
to
toc
oto
toc
tary
eet
ppo
per
son
e m
pro
o co
e pr
pro
ecre
pro
pos
e ge
ner
46
7 7
49 7
3. A
l of
ual
for
201
6.
ort
ppr
ova
ann
rep
7 74
9 74
6
4. A
l of
fit a
nd l
and
ba
lanc
e sh
201
6.
eet
ppr
ova
pro
oss
7 74
9 74
6
5. A
l of
the
dis
trib
utio
n of
the
fit f
he y
or t
ppr
ova
pro
ear
7 74
9 74
6
6. T
he B
d of
Dir
r's d
ecla
rati
lary
and
oth
rati
o th
ecto
on t
ent
oar
on o
n sa
er r
em
une
e m
ana
gem
6 0
76 8
74
72
1 6
72 8
l of
fee
he a
udit
or f
or 2
016
7. A
to t
ppr
ova
9 74
6
7 74
8. E
lect
ion
of b
d m
ber
of t
he b
d m
ber
ele
ctio
his
is a
rdin
The
min
atio
itte
e's
tion
s. T
n. T
g to
No
n Co
oar
em
wo
oar
em
s ar
e on
cco
mm
sug
ges
46
49 7
7 7
the
ard
. Th
is is
ord
ing
he N
inat
ion
mit
's su
stio
9. F
to
Bo
to t
Com
tee
ees
acc
om
gge
n.
7 74
9 74
6
The
mbe
he N
inat
ion
mit
. Th
is is
ord
ing
he N
inat
ion
mit
's su
stio
10.
rs t
Com
tee
to t
Com
tee
me
om
acc
om
gge
n.
46
7 7
49 7
sati
o th
inat
ion
mit
. Th
is is
ord
ing
he N
inat
ion
mit
's su
stio
11.
Com
on t
e N
Com
tee
to t
Com
tee
pen
om
acc
om
gge
n.
74
6 4
01 8
72
1 3
47 8
l of
the
ard
of
r's s
o th
al m
he B
d of
r's a
uth
e sh
ital.
12.
App
Bo
Dire
cto
esti
on t
eet
ing
to r
w t
Dir
ecto
oriz
atio
n to
inc
rova
ugg
e ge
ner
ene
oar
reas
are
cap
46
7 7
49 7
l of
the
ard
of
r's s
the
of
rcha
sha
13.
App
Bo
Dire
cto
esti
on t
atto
y to
rova
ugg
o re
new
po
wer
rne
pu
se o
wn
res
46
7 7
49 7

Shareholders at the General Meeting:

Asb
jørn
bu
ane
ss
519
936
Inte
de s
hipp
ing
rtra
4 00
3 50
0
Kar
i Kr
tad
ogs
100
000
Tho
Jak
obs
mas
en
70 0
00
Me
dist
im A
SA's
e ak
sjer
egn
176
000

Total number of shares outstanding 18 337 336

icip
atio
n th
gh p
Part
rou
roxy
Pro
xy t
o
Pre
vot
e
nde
eak
glo
bal
ch f
und
Gra
ur P
Rea
an Ø
Cha
irm
yvin
75 1
50
Brø
yme
r
In f
n al
l ite
avo
ur o
ms
nde
eak
glo
bal
nitie
s fu
nd
Gra
ur P
Opp
ortu
an Ø
Cha
irm
yvin
152
700
Brø
yme
r
In f
n al
l ite
avo
ur o
ms
nde
eak
glo
bal
iona
l
Gra
ur P
Inte
rnat
an Ø
Cha
irm
yvin
420
559
Brø
yme
r
In f
n al
l ite
avo
ur o
ms
aplu
fon
ds 1
NN
Par
N.V
an Ø
Cha
irm
yvin
183
309
Brø
yme
r
In f
n al
l ite
avo
ur o
ms
nde
eak
glo
bal
Gra
ur P
Opp
ortu
nitie
s L.
P
an Ø
Cha
47 5
00
irm
yvin
Brø
yme
r
In f
n al
l ite
avo
ur o
ms
nde
eak
k G
lob
FIN
inv
tst
Gra
ur P
Mic
ro
an Ø
Cha
25 8
62
irm
yvin
Brø
yme
r
In f
n al
l ite
avo
ur o
ms
Seb
all c
Eu
rop
eea
n sm
aps
an Ø
Cha
325
000
irm
yvin
Brø
yme
r
In f
n al
l ite
ber
ept
6
avo
ur o
ms
exc
nu
m
dba
nk R
orb
knik
Swe
y te
ur n
an Ø
Cha
1 34
7 87
2
irm
yvin
Brø
yme
r
In f
n al
l ite
mbe
d 11
6 an
ept
avo
ur o
ms
exc
nu
r
Me
QIF
FU
ND
PLC
rcer
an Ø
Cha
162
358
irm
yvin
Brø
yme
r
Abs
the
fa
all
tain
item
1 o
rwis
e in
item
on
vou
r on
s
lix
Rigm
or B
Tho
Jak
obs
140
000
CFO
mas
en
In f
n al
l ite
avo
ur o
ms
of
l nu
mbe
r of
sha
In %
tota
res
al n
ber
of s
har
eho
lder
ted
he m
Tot
ing
at t
eet
um
s re
pre
sen
7 74
9 74
6
42,
26 %
al n
ber
of s
har
eho
lder
ted
he m
thro
ugh
Tot
ing
at t
eet
um
s re
pre
sen
pro
xy
2 88
0 31
0
15,
71 %

Talk to a Data Expert

Have a question? We'll get back to you promptly.